Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp112 | Cell biology: osteoblasts and bone formation | ECTS2014

Levels of circulating vesicular microRNA-31 increase with age as well as in the case of osteoporosis and inhibit osteogenic differentiation capacity of mesenchymal stem cells

Weilner Sylvia , Schraml Elisabeth , Wassermann Klemens , Wieser Matthias , Messner Paul , Schneider Karl , Micutkova Lucia , Fortschegger Klaus , Maier Andrea B. , Westendorp Rudi , Resch Heinrich , Wolbank Susanne , Redl Heinz , Jansen-Durr Pidder , Pietschmann Peter , Grillari-Voglauer Regina , Grillari Johannes

Aging is a complex process that results in the decline of physiologic functions due to accumulation of damage in cells and tissues. Mesenchymal stem cells (MSCs) counteract this decline but their regeneration capacity decreases with age. In particular osteogenic differentiation potential of MSCs has been shown to decrease with age thereby contributing to slowed down bone formation and osteoporosis. While much is known about cellular aging of MSCs, little is known about factors...

ba0005oc5.1 | Risk factors for fracture, Pagets disease of bone and musle and bone | ECTS2016

High serum miRNA 550a-5p levels are risk factors for incident fractures in older postmenopausal women with type 2 diabetes

Heilmeier Ursula , Hackl Matthias , Skalicky Susanna , Weilner Sylvia , Schroeder Fabian , Vierlinger Klemens , Lobach Iryna , Eiriksdottir Gudny , Aspelund Thor , Gudmundsson Elias , Grillari Johannes , Harris Tamara , Link Thomas , Gudnasson Vilmundur , Schwartz Ann

Standard DXA measurements, including FRAX scores, are limited in assessing fracture risk in type 2 diabetes (T2D). Novel, general applicable biomarkers are therefore needed. MicroRNAs (miRNAs) are secreted into the circulation from cells of various tissues proportional to local disease severity. Serum miRNA classifiers including miR-550a-5p were recently found to discriminate T2D women without and with prevalent fragility fractures with high specificity and sensitivity (AUC&#6...

ba0001pp429 | Osteoporosis: treatment | ECTS2013

Study description and baseline characteristics of the population enrolled in the extended forsteo® observational study (ExFOS)

Langdahl Bente , Benhamou Claude , Lindh Erik , Dekker Joannes , Kapetanos Giorgios , Kocjan Tomaz , Ljunggren Osten , Napoli Nicola , Petto Helmut , Nicolic Tatjana

ExFOS is a multicenter, prospective, observational study to evaluate fracture outcomes, back pain, compliance and health-related quality of life in female and male patients with osteoporosis treated with teriparatide [rhPTH(1–34)] (Forsteo)for 18 to 24 months. Post-treatment follow-up will last for at least 18 months. Patients were enrolled in Croatia, Denmark, France, Greece, Italy, Norway, Slovenia, and Sweden. The study design was non-interventional and all consenting ...

ba0001pp129 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

The Ellsworth-Howard test revisited

Tang J C Y , Washbourne C J , Galitzer H , Hiemstra T , Meek C , Chipchase A , Fraser W D

Background: Pseudohypoparathyroidism (PHP) is a group of heterogeneous endocrine disorders characterised by hormone resistance, primarily to parathyroid hormone (PTH). The resistance is caused by defects in the GNAS gene, which encodes the Gsα protein that activates the cAMP pathway. PHP patients demonstrate elevated plasma PTH, hypocalcaemia, hyperphosphataemia with normal renal function. PTH resistance can be confirmed by Ellsworth-Howard test (PTH s...

ba0007is14 | (1) | ICCBH2019

Orthopedic needs in X-linked hypophosphatemic rickets

Ganger Rudolf Radler C , Ganger Rudolf

To point out common patterns of malalignment and deformity in hypophosphatemic rickets and describe treatment principles and techniques as well as common obstacles.Methods: Deformities of the lower limb in hypophosphatemic rickets do not resolve spontaneously under metabolic control of the disease. To prevent severe deformity and joint overload in the growing child guided growth has been shown to be effective in most cases. As recurrence of malalignment ...

ba0001oc1.1 | Osteoporosis epidemiology and long term treatment complications | ECTS2013

Disease-specific perception of fracture risk and incident fracture rates among postmenopausal women: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)

Gregson Celia , Dennison Elaine , Compston Juliet , Adami Silvano , Adachi Jonathan , Anderson Frederick , Boonen Steven , Chapurlat Roland , Diez-Perez Adolfo , Greenspan Susan , Hooven Frederick , Lacroix Andrea , Nieves Jeri , Netelenbos J Coen , Pfeilschifter Johannes , Rossini Maurizio , Roux Christian , Saag Kenneth , Silverman Stuart , Siris Ethel , Watts Nelson , Wyman Allison , Cooper Cyrus

Patients with improved health understanding have greater autonomy over, and motivation towards, health-related lifestyles. We compared self-perceived fracture risk and 3-year incident fracture rates in postmenopausal women for a range of co-morbid diseases using data from the Global Longitudinal study of Osteoporosis in Women (GLOW).GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America, Austr...

ba0003cc4 | (1) | ECTS2014

Two novel compound heterozygous mutations in LRP5 cause osteoporosis pseudoglioma syndrome

Alonso N , Soares D C , Kabir D , Summers G D , Ralston S H , Gregson C L

Osteoporosis pseudoglioma syndrome (OPPGS) is a rare autosomal recessive disorder characterised by congenital or juvenile-onset blindness, severe juvenile-onset osteoporosis, and skeletal fragility. OPPGS is caused by loss-of-function mutations in the LRP5 gene, a member of the LDL receptor family. It activates the canonical Wnt/β-catenin pathway, regulating osteoblastic bone formation. We investigated a 40-year-old Caucasian male presenting with congenital blind...

ba0001pp449 | Osteoporosis: treatment | ECTS2013

Odanacatib treatment reduces remodeling- and stimulates modeling-based bone formation in adult OVX monkeys

Chen C , Shih M , Zheng H , Duong L

Odanacatib (ODN), a selective and reversible cathepsin K inhibitor was shown to histomorphometrically reduce trabecular (Tb) and intracortical (Ic) bone remodeling while preserving endocortical (Ec) and stimulating periosteal (Ps) bone formation (BF) in monkeys. Here, we investigate the bone site specific mechanism of ODN on bone modeling (Mo) versus remodeling (Re)-based osteons. Rhesus monkeys (13–19 yrs, n=8–11/group) were ovariectomized and treated with ...

ba0003pp114 | Cell biology: osteoblasts and bone formation | ECTS2014

N-linked glycosylation as a critical mechanism of PTH-resistance in osteoblasts in high glucose conditions

Picke Ann-Kristin , Hamann Christine , Rauner Martina , Hofbauer Lorenz C.

Type 2 diabetes mellitus impairs bone quality and increases fracture risk. We showed that diabetic ZDF rats have low bone mass due to impaired osteoblastogenesis, which can be partially reversed with an intermittent parathyroid hormone 1–84 (PTH) therapy. It remains unclear, why PTH treatment does not fully restore osteoblast (OB) function in diabetic conditions. Here, we tested if high glucose (HG) conditions lead to a partial PTH resistance in osteoblasts. Pre-osteoblas...

ba0004p197 | (1) | ICCBH2015

Benign osteopetrosis associated with homozygous mutation in CLCN7

Allgrove Jeremy , Mathew Satheesh , Buxton Chris C , Williams Maggie

Introduction: Benign osteopetrosis type 2 (OPTA2) (Albers-Schönberg disease) is usually associated with a heterozygous mutation in CLCN7. Patients may be asymptomatic and present following an x-ray taken for other reasons or with a low trauma fracture. There may be a family history. Homozygous mutations in CLCN7 usually result in severe disease which presents in the neonatal period or early infancy. We present a case of benign osteopetrosis associated wi...